KDIGO Criteria for Acute Kidney Injury and Chronic Kidney Disease
The KDIGO criteria provide standardized definitions for diagnosing and staging both acute kidney injury (AKI) and chronic kidney disease (CKD), with AKI defined by rapid changes in serum creatinine or urine output over hours to days, while CKD requires persistent kidney abnormalities lasting more than 3 months. 1, 2
Acute Kidney Injury (AKI) Definition and Staging
Diagnostic Criteria for AKI
AKI is diagnosed when any one of the following occurs 2:
- Serum creatinine increase ≥0.3 mg/dL (26.5 μmol/L) within 48 hours, OR
- Serum creatinine increase to ≥1.5 times baseline within 7 days, OR
- Urine output <0.5 mL/kg/hour for 6 hours
AKI Staging System
Stage 1 2:
- Serum creatinine 1.5-1.9 times baseline OR ≥0.3 mg/dL increase, OR
- Urine output <0.5 mL/kg/hour for 6-12 hours
Stage 2 2:
- Serum creatinine 2.0-2.9 times baseline, OR
- Urine output <0.5 mL/kg/hour for ≥12 hours
Stage 3 2:
- Serum creatinine ≥3.0 times baseline OR increase to ≥4.0 mg/dL (353.6 μmol/L), OR
- Initiation of renal replacement therapy, OR
- In patients <18 years: eGFR decrease to <35 mL/min/1.73 m², OR
- Urine output <0.3 mL/kg/hour for ≥24 hours OR anuria for ≥12 hours
Important Caveats for AKI Diagnosis
The KDIGO definition has not been validated in patients with pre-existing CKD, where small creatinine fluctuations (e.g., 4.0 to 4.3 mg/dL) may represent normal daily variation rather than true AKI 2. Exercise caution when applying the 0.3 mg/dL criterion to CKD patients, as this may lead to overdiagnosis.
Acute Kidney Disease (AKD)
AKD bridges the gap between AKI and CKD, defined as 1, 3:
- Duration: 7 days to 3 months after kidney injury
- Includes AKI that persists beyond 7 days
- Also encompasses subacute kidney damage with markers like hematuria, pyuria, or GFR <60 mL/min/1.73 m² for <3 months
- Does not require the rapid functional decline characteristic of AKI
Chronic Kidney Disease (CKD) Definition
CKD requires abnormalities persisting for >3 months 1:
Diagnostic Criteria (either criterion sufficient)
- GFR <60 mL/min/1.73 m² for ≥3 months (with or without kidney damage), OR
- Markers of kidney damage for ≥3 months (with or without decreased GFR), including:
- Structural abnormalities on imaging
- Functional abnormalities (proteinuria, hematuria)
- Pathological findings on biopsy
CKD Staging by GFR Category
While the evidence provided doesn't detail all CKD stages, the guidelines reference a comprehensive staging system based on GFR categories (G1-G5) and albuminuria categories (A1-A3) 4. The complete classification requires both cause identification and risk stratification using these categories.
Clinical Implementation Algorithm
For suspected kidney dysfunction:
Measure serum creatinine and urine output - compare to baseline if available
Determine timeframe of changes:
- <48 hours with 0.3 mg/dL rise → AKI
- <7 days with 1.5× baseline rise → AKI
- 7 days to 3 months → AKD
3 months → CKD
Stage severity using appropriate criteria for AKI (Stages 1-3) or CKD (G and A categories)
Evaluate at 3 months post-AKI 2, 5:
- If CKD develops → manage per CKD guidelines
- If no CKD → consider at increased risk for future CKD
Key Practical Points
The KDIGO criteria allow heterogeneity within Stage 1 AKI - a 0.3 mg/dL increase represents a much smaller percentage change in patients with higher baseline creatinine compared to the 50% increase criterion 2. This creates a diagnostically diverse group requiring individualized assessment.
Urine output criteria are underutilized in clinical practice because most epidemiologic studies lack these data, yet they remain part of the formal definition 2.
Proof of chronicity for CKD can be established through review of prior measurements, imaging showing reduced kidney size, pathological findings, or simply repeating tests beyond the 3-month threshold 4.